GI Innovation inks clinical trial collaboration with MSD

[Courtesy of GI Innovation]

South Korea’s GI Innovation said on Monday that it signed a clinical trial collaboration and supply agreement with global pharmaceutical company MSD.

Under the agreement, the duo will conduct a trial to evaluate the efficacy of their immunotherapies in combination. The two companies will also evaluate the efficacy of GI Innovation’s immuno-oncology drug GI-102 in combination with MSD’s Keytruda in patients with resistant liver cancer, melanoma, and kidney cancer.

GI Innovation said GI-102 is a treatment that increases the number of immune cells by an average of fivefold, demonstrating potent cancer-fighting immune cell proliferation.